One advantage I have of weekly blood tests is that I can try things and see what happens. I would need to drop back some of the interventions I am using at the moment, but there is at least possibly an argument for taking it together with rapamycin. It may have a broader benefit as well. I should be noted, however, that it is generally not metabolised only really excreted.
3 Likes
I looked through the papers on imeglimin, and the only phrase that comes to mind is that it feels like a chicken rib: too tasteless to enjoy, yet a pity to throw away. Maybe my perspective will change years down the line.
2 Likes
Here is the Human study mentioned earlier in this thread:
Strength Without Size: A Mitochondrial Diabetes Drug Made Legs Stronger Without Adding a Gram of Muscle
A Japanese observational cohort followed 50 people with type 2 diabetes for 24 weeks and compared 23 who were newly started on imeglimin, a first-in-class oral drug that targets mitochondria, against 27 who were not. Quadriceps knee extension strength rose 13 percent in the imeglimin group versus 2.1 percent in controls, a difference that held up after adjusting for age, sex, BMI, and muscle mass index. Grip strength did not differ. Critically, lean body mass, fat mass, and skeletal muscle index were unchanged in both groups. The strength gain therefore came from something other than muscle growth, which the authors attribute to improved mitochondrial function inside existing muscle fibres. The study was small, non-randomised, unblinded, and the effect was statistically fragile.
Muscle strength and muscle size usually travel together. Get stronger, and you generally have more muscle to show for it. A small Japanese study has just reported a case where they came apart.
Researchers at St. Marianna University School of Medicine in Kawasaki followed 50 outpatients with type 2 diabetes over six months. Twenty-three had just been started on imeglimin, sold in Japan as Twymeeg and the first drug in a new class that works by acting directly on mitochondria, the structures that convert food and oxygen into usable cellular energy. The other 27 stayed on whatever they were already taking. Everyone had their thigh strength, grip strength, and body composition measured at the start and again at 24 weeks.
The thigh result is the headline. Knee extension strength in the imeglimin group rose by 13 percent on average. In the comparison group it rose 2.1 percent, which is roughly measurement noise. In absolute terms the drug group gained 3.6 newton-metres of torque against 0.5 in controls. Grip strength, by contrast, barely moved in either group.
The part that makes this interesting to anyone thinking about ageing is what did not happen. Lean body mass did not increase. Neither did fat mass, nor the skeletal muscle index derived from DEXA scanning. The muscles did not get bigger. They apparently got better at generating force with the tissue already there.
That points at muscle quality rather than muscle quantity, and quality is largely a mitochondrial story. Ageing muscle accumulates mitochondria that leak reactive oxygen species and generate less energy per unit of tissue, a decline that tracks closely with slower walking and greater fatigue in older adults. Imeglimin has been shown in animal and cell work to partially inhibit one part of the mitochondrial respiratory chain while restoring another, increasing mitochondrial DNA content and lowering reactive oxygen output. If that also happens in human leg muscle, stronger legs without bigger legs is the expected signature.
The idea matters because most modern diabetes drugs push in the opposite direction. GLP-1 receptor agonists and SGLT2 inhibitors reliably reduce body weight, and a meaningful fraction of what they remove is lean tissue. A glucose-lowering agent that leaves muscle mass alone while improving what that muscle can do would be a genuinely different proposition for older patients.
The caveats are large. Nobody was randomised, nobody was blinded, and doctors chose who got the drug. The statistical margin was thin. The authors themselves call for randomised trials, and they are right to.
Insights
On magnitude: the standardised effect size for the thigh strength difference is Cohen’s d of about 0.66. In plain terms, that means if you picked one imeglimin patient and one control at random, there is roughly a 68 percent chance the imeglimin patient improved more, versus 50 percent if the drug did nothing. That is a moderate, not dramatic, effect, and the confidence interval runs from 0.09 to 1.23, meaning the true effect could be trivially small or quite large. The study cannot tell you which.
The transferable insight is the dissociation itself. Strength and size are separable, and strength is the outcome that actually predicts falls, disability, and mortality. Anyone tracking sarcopenia should be measuring force output, not just DEXA lean mass. A stable lean mass reading does not mean function is stable.
Context and Source
- Open Access Paper: The Effects of Imeglimin on Muscle Strength in Patients with Type 2 Diabetes: A Prospective Cohort Study
- Institution: Department of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
- Journal: Diabetes Therapy (Adis / Springer Healthcare), 2024.
- Impact evaluation: The impact score of this journal is 4.2 (2025 Journal Impact Factor as listed by the publisher; 5-year JIF 3.7; SJR 1.137, Q1 in Endocrinology, Diabetes and Metabolism), evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is a Medium impact journal.
3 Likes
I started taking it about 3 weeks ago and feel incredible. My blood work was normal before but I suspect there was some glucose disruption at night that would keep me awake at 4am. I can now sleep like I used to, not hungry in am. I would rank my improvement up there with rapamycin and I think it pretty much saved my life. My partner who is clearly prediabetic been taking it for about 2 weeks. He wore CGM and effects are very clear- lower average glucose, tighter peaks, glucose actually drops after dinner and thru the night
6 Likes
The rough pricing I’ve seen from Indian pharmacies for Imeglimin products are:
Imeglyn by Zydus Pvt Ltd. - 1000mg- 20$ / 100 tablets ($0.20 per tablet).
3 Likes
I am scheduled for my next blood labs next Wednesday and will provide an update when I receive the results.
Additionally, I found that a 1500mg BID dosage was more effective in the European population than the 1000mg BID dosage used in Japan. In fact the 1000mg BID dose might not be enough for a western population.
That is why I am currently taking 1000mg three times per day. I am splitting the dosage rather than taking 1500mg at once to avoid GI issues.
Here is Claude 5’s perspective on this dosage:
Two parallel Phase 2b dose-ranging programs, two different answers
Poxel ran essentially the same design (500 / 1000 / 1500 mg BID vs placebo, 24 weeks) in Western and Japanese populations, and they diverged:
- Western trial (n=382, topline Dec 2014, presented as a poster at ADA 2015 by Fouqueray): the primary HbA1c endpoint was met versus placebo (p<0.001) with a significant FPG decrease at the 1500 mg dose, which was designated as the dose to carry into Phase 3. HbA1c fell dose-dependently with 1500 mg BID most effective (placebo-adjusted −0.63%, p<0.001), 33.3% of patients on 1500 mg BID reached HbA1c ≤7% vs 12.5% on placebo (p=0.005), and maximum efficacy at all doses was reached by 18 weeks. Poxel’s framing at the time was that 1500 mg BID was both the most active and well-tolerated, and therefore the optimal Phase 3 dose.
- Japanese trial (Dubourg et al., Diabetes Obes Metab 2021, n=299): placebo-adjusted HbA1c was −0.52% at 500 mg, −0.94% at 1000 mg and −1.00% at 1500 mg BID. Because the 1500 mg increment over 1000 mg was marginal and carried a GI tolerability penalty, 1000 mg BID was selected for the Phase 3 TIMES program — and that is what got approved.
Why the difference
Population PK modelling attributes it mostly to exposure, not to ethnicity per se. Japanese patients showed somewhat higher imeglimin exposures than Western patients at the same dose, and simulations indicated the Japanese/Western AUC gap at identical doses was driven mainly by eGFR differences — about +15 mL/min/1.73 m² in the Western cohorts. Imeglimin is not metabolized and eliminated unchanged in urine, so renal function dominates. Same reasoning drives the renal dose reduction: 500 mg BID for eGFR 15–45.
One caveat on the “better results” framing
Within-trial, yes — 1500 mg was the top of the dose-response curve in Westerners. Across trials, no: the Western 1500 mg effect (−0.63%) was smaller in absolute terms than Japanese 1000 mg (−0.94%). A meta-analysis group also flagged that the Fouqueray Western study found non-significant HbA1c lowering at both 500 and 1000 mg BID versus placebo, which is part of why the dose-response there pushed higher — the lower doses simply underperformed in that cohort. That trial was also never published in full peer-reviewed form, only as the ADA poster.
Supporting Western data at 1500 mg BID
The one properly published Western study using that dose is Theurey et al., Endocrinol Diabetes Metab 2022 (EudraCT 2013-001539-35): 18 weeks, 1500 mg BID vs placebo in 59 metformin-washed-out patients across Hungary, Latvia and Romania, with glucose AUC −429.6 mmol/L·min (p=0.001) and HbA1c −0.62% (p=0.013) — the authors themselves noted this was modest relative to the Japanese data at 1000 and 1500 mg.
Tolerability ceiling: GI events increase dose-dependently from 1500 mg upward to the maximal tolerated 6000 mg, mostly mild nausea, vomiting and diarrhea.
The Western Phase 3 program at 1500 mg BID was never completed, so that dose has never been validated in a registrational trial — the evidence for it is one unpublished Phase 2b poster and one small mechanistic study. Worth discussing with whoever manages your glycemic control before extrapolating, particularly since renal function is the variable that actually determines your exposure at any given dose.
5 Likes
tnx alot!!! I had no idea dosing could go so high to achieve best glucose control plus the systemic beneficial side effects. I’ll not be shy with my afternoon prior to dinner dose!!
tnx curt
1 Like
I was curious about the exact side effect profile for imeglimin (I’ve never had any side effects, but have only taken it once per day (1,000mg).
Its amazingly benign… basically a side effect profile that is almost identical to placebo, up to 2, or 3 grams per day.
Here is the full report:
2 Likes
The question I have is, should it be used in combination with Metformin or as a replacement for it? My mother is on 2 g of Metformin daily, and 1.5 g of Imeglimin would probably have a lesser effect on her HBA1C. However, I worry about mixing these two medications.
That info is in the report. I included info on possible combinations like metformin (a biguanide class drug). See below the side effects when added:
2 Likes
DDI pretty benign combined with acarbose. Still some serious events, but overall OKish as these things go.
I’m also curious if there’s any effect with various SGLT2i, though it seems pretty different MOA, so not direct interaction, rather ultimate outcome as the body strives for homeostasis. I have a kind of suspicion - can’t even call it a hypothesis - that when we gradually develop tolerances to meds, or meds seem not as effective as they should be on paper, it’s because the body is working hard to get back to its previous balance through various compensatory mechanisms. Sort of how the body fights to maintain weight even as you cut calories. And that’s how I can take BA, EZ and pita all at max doses and my LDL levels are not that much affected; empa and A1c stays put, all impervious to diet and exercise. YMMV.
3 Likes
I think it all depends. My parents and I take Pitavastatin, Bempedoic Acid and Ezetemibe and get our Apob in the 25-55 range. I’m the highest at 53! Everyone has a unique biology. Just like I and my mother are statin intolerant.
1 Like
When imeglimin is combined with metformin, the incidence rates of diarrhea and nausea reach as high as 15.6% and 10.9% respectively, which is significantly higher than with monotherapy or other combination regimens.
1 Like
From my perspective (an obsession with mitochondria and acetylation) it arguably would reduce ROS which reduces the creation of deletions in mtDNA, it also would improve ⟨ΔΨm⟩ which would improve gene expression. However, it would act as a prop rather than encouraging mitophagy (and particularly fission-mitophagy-fusion). Hence it looks like something worth taking with Rapamycin, but not something that would replace Rapamycin.
2 Likes
Imeglimin, especially in combination with non-Metformin OHAs, improves glycemic control and reduces mitochondrial and inflammatory stress in T2DM patients. These findings support its use as an adjunctive therapy with broader metabolic benefits.
3 Likes
Please, share your experience how you mix antilipids medications? What dosages, and what numbers you’ve got and achieved with them. Really important info, thanks
Hi @egorvj, that’s a lot of data I would have to gather. But, I already did that in 2025, I had several blood tests every few months starting April 2025:
and then every few months, June, August and so on, with details on all the LLT drugs, their individual and combined effects, all experiments on myself.
If you go to that thread “Cardiovascular Health 2025”, and look for my posts, you will find all the details - it’s too much data to recreate for me here, but go through that thread starting with the April post I linked to above, and then go through the rest of that thread to find my detailed posts. Good luck!
2 Likes
thanks for sharing!
• Has anyone taken the sustained-release (SR) form of imeglimin?
• Does the extended-release version last longer or gentler on the stomach compared to the regular immediate-release (IR) form?
• Is it worth spending extra money to buy the extended-release formulation?
I checked online and found that the regular form needs to be taken twice a day at 1,000 mg each time, while the extended-release form is taken once a day at 2,000 mg. It seems that the extended-release form is much more convenient to take.
Here is the quote I received:
Product Details:
• Product Name: IMEglyn 1000 Tablet
• Active Ingredient: Imeglimin (1000mg)
• Manufacturer: Zydus Healthcare Limited
• Packing: 10 Tablets in 1 Strips
Price Options (Shipping Included):
• Option 1 : USD 108 for 60 Strip (600 Tablets)
• Option 2 : USD 154 for 100 Strip (1000 Tablets)
• Option 3 : USD 208 for 150 Strip (1500 Tablets)
Product Details:
• Product Name: IMEglyn SR 1000mg Tablet
• Active Ingredient: Imeglimin 1000 mg Sustained release
• Manufacturer: Zydus Healthcare Limited
• Packing: 10 tablets per strip
Price Options (Shipping Included):
• Option 1: USD 152 for 60 strips (600 tablets)
• Option 2: USD 223 for 100 strips (1000 tablets)
• Option 3: USD 314 for 150 strips (1500 tablets)
3 Likes
Good questions. I’m considering doing a longer trial of Imeglimin, so your points are something I need to consider. After reviewing the information below, I think I’d just go with the regular Imiglimin and dose twice a day (Morning and Evening).
Here is what Claude 5.5 Says:
Bottom line: Imeglimin SR is mainly a convenience product. Its once-daily dosing is real. The claims that it “lasts longer” and is “gentler on the stomach” are plausible from formulation logic, but no published data I could find show either. The price difference is small enough that cost shouldn’t decide it; tolerability and adherence should.
What exists
The originator, Twymeeg (Sumitomo, Japan), is immediate-release only. It was approved in Japan in June 2021 as 500 mg tablets. SR versions are Indian products. Examples include Torrent’s Imextor SR, Zydus’s Imeglyn SR and La Renon’s Imezemic SR, all 1000 mg. Imextor SR uses an HPMC hydrophilic matrix, the same general approach as most metformin XR tablets. The label converts doses as follows: poxelpharma
- 500 mg IR twice daily becomes one 1000 mg SR tablet once daily. torrentpharma
- 1000 mg IR twice daily becomes two 1000 mg SR tablets taken together once daily, after a meal, with a 2000 mg/day ceiling. torrentpharma
Reasons someone might choose SR
- Once-daily dosing. This is the main legitimate reason. It helps people who miss the evening dose, shift workers, or anyone already on a once-daily regimen (for example metformin XR plus an SGLT2 inhibitor).
- A smoother concentration curve, in theory. IR peaks early: a single 1000 mg fasting dose reached tmax around 2.5 h with Cmax ~1393 ng/mL. A matrix tablet should blunt that peak. torrentpharma
- Possibly fewer GI symptoms. This rests on the metformin XR precedent, not on imeglimin data.
Does it last longer?
There’s no public evidence that it does. The drug’s terminal half-life is already reasonably long: the apparent half-life ranges from 9 to 20 h, typically around 13 h at therapeutic doses. That partly explains why once-daily dosing can work at all. springer
The SR label itself raises a red flag. Its pharmacokinetic tables look like IR bioequivalence data:
- Reference Cmax ~1538 ng/mL, tmax ~2.5 h, t½ ~3.9 h torrentpharma
- Test Cmax ~1547 ng/mL, tmax ~2.8 h torrentpharma
- The graph is captioned “Imeglimin HCl Tablets 1000 mg”, with no SR designation. torrentpharma
A real extended-release profile would show a clearly lower Cmax and a later tmax. I found no published single-dose or steady-state PK curve comparing SR with IR.
Is it gentler on the stomach?
This is unproven, and there’s limited room to improve. At the approved dose, IR is already well tolerated. In the Japanese phase 2b trial, adverse drug reaction rates were 5.3% at 500 mg, 5.4% at 1000 mg, 24.0% at 1500 mg, and 8.0% on placebo. GI problems mostly appear above the approved dose. torrentpharma
One detail cuts against SR. In a CKD study, GI events trended lower with 1000 mg twice daily than with 1500 mg once daily, despite higher systemic exposure with the former. That suggests GI effects follow the size of each dose in the gut, not blood levels. Full-dose SR puts 2000 mg into the gut at once. Whether the HPMC matrix offsets that is unknown. uspto
Two further pharmacology points matter here:
- Incomplete absorption. About 42% of a radiolabeled dose was recovered unchanged in urine and 54.8% of radioactivity in feces, so roughly half the drug is not absorbed. If absorption depends on the upper small intestine, as it does for metformin through OCT transporters, slower release could lower bioavailability or push more drug into the colon. This is a hypothesis, not a finding. torrentpharma
- Combining with metformin. The label warns that GI symptoms tend to occur more often with biguanide co-administration, especially early. That holds regardless of formulation. torrentpharma
The only SR clinical trial I found is an Indian phase III, active-controlled study of SR 1000 mg once daily. The authors say SR showed greater HbA1c, FPG and PPG reductions at week 16 than imeglimin IR. That appears to be a comparison with other studies, not a head-to-head arm, and I couldn’t access the full text to check. It also used half the standard 2000 mg/day dose. ovid
Is it worth the extra money?
In India (India-pricing, not export pricing) the premium is trivial and depends on the brand:
| Product (10 tablets, 1000 mg) | MRP |
|---|---|
| Zydus Imeglyn IR | ₹110.99 |
| Zydus Imeglyn SR | ₹122.72 |
| Torrent Imextor SR | ₹158.40 |
| Steris Imeglimon IR | ₹262.50 IMEGLYN 1000MG TABLET 10’S +3 |
At an equivalent dose you take the same number of 1000 mg tablets either way. Within one brand, SR costs roughly ₹1–2 more per day. Choosing a different brand changes the cost more than switching IR to SR does.
My take:
- SR is reasonable for anyone whose problem is missed doses, or as a cheap trial for someone with GI symptoms on IR after taking it with food and lowering the dose.
- Stay on IR if it’s working. IR has the Japanese phase III and long-term data behind it. The 500 mg IR tablet also allows finer titration, which matters in renal impairment, because exposure rises substantially as renal function declines. SR tablets can’t be split or crushed.
Google Gemini Response to the Same Prompt:
The primary pharmacology driving interest in SR formulations revolves around dosing simplification (once daily vs. twice daily), pharmacokinetic peak dampening , and gastrointestinal (GI) tolerability mitigation .
1. Does the Extended-Release Version Last Longer?
Yes, clinically and functionally, though not via alteration of intrinsic clearance.
-
Absorption vs. Elimination Kinetics: In its IR formulation, imeglimin displays rapid absorption with a TmaxTmaxof 1.0 to 3.5 hours. Its terminal elimination half-life (t1/2t1/2) ranges between 4.5 and 12 hours (extending up to 20 hours in Caucasian pharmacokinetic studies, largely governed by renal clearance through organic cation and multidrug/toxin extrusion transporters like OCT1, OCT2, and MATE2-K). Due to rapid initial distribution and clearance from the central compartment, IR dosing must be administered BID to maintain consistent, therapeutic systemic exposure throughout 24 hours.
-
Flip-Flop Pharmacokinetics in SR: The SR/ER matrix slows the dissolution and mucosal absorption rate constant (kaka) such that absorption becomes slower than elimination (ka<keka<ke). This shifts TmaxTmax further out and broadens the plasma concentration-time profile.
-
Dosing Frequency: Because the apparent duration of absorption is extended, an SR formulation allows once-daily (QD) administration (e.g., 1,000 mg to 2,000 mg QD taken post-meal) instead of splitting into morning and evening doses. The total daily drug exposure (Area Under the Curve, AUC0−24AUC0−24) remains bioequivalent, but plasma drug levels avoid the steep trough drops seen toward the end of an IR 12-hour interval.
2. Is It Gentler on the Stomach Compared to Regular IR?
Pharmacologically yes, though supported largely by mechanistic and class-extrapolated data rather than extensive head-to-head clinical trials.
-
Mechanism of GI Distress: While imeglimin demonstrates a significantly better overall GI safety profile than metformin, gastrointestinal adverse events (including nausea, upper abdominal pain, dyspepsia, and loose stools) remain its most frequently reported side effects, occurring in roughly 5% to 15% of patients across the TIMES clinical development program and post-marketing cohorts. These symptoms stem from two concurrent factors:
- Local upper-GI mucosal irritation: High local concentrations of the salt dissolving rapidly in the stomach and upper duodenum.
- Transient systemic peak spikes: A steep CmaxCmax can provoke central and enteric serotonergic/vagal nausea pathways.
-
The SR Advantage: By utilizing a sustained-release polymer or matrix system, the drug is released gradually across a longer transit path in the intestinal lumen. This eliminates the rapid, high-concentration local mucosal “surge” and lowers the maximum peak plasma concentration (CmaxCmax) relative to an equal single IR bolus.
-
Scholarly Debate & Knowledge Gaps:
-
The assumption of superior GI tolerability is directly modeled on decades of evidence from metformin IR versus metformin ER/XR , where extended release reliably slashes GI discontinuation rates by 50% or more.
-
For imeglimin specifically, bioequivalence and Phase III/IV regulatory studies in India confirm that SR 1000 mg is effective, well-tolerated, and comparable to baseline safety standards. However, large-scale, double-blind, head-to-head randomized trials specifically scoring upper-GI symptoms between imeglimin IR and SR remain absent in peer-reviewed literature. Much of the tolerability claim rests on established biopharmaceutical principles and post-marketing clinical observation rather than published superiority trials.
-
3. Is It Worth Spending Extra Money to Buy the Extended-Release Formulation?
The cost-benefit analysis breaks down across three variables:
A. Regimen Adherence and Dosing Burden
- A major cause of secondary oral antidiabetic failure is poor compliance with twice-daily regimens. If skipping the evening IR dose occurs regularly, the once-daily convenience of SR significantly improves therapeutic consistency,maintaining stable mitochondrial target engagement. If once-daily compliance directly protects glycemic stability,SR is clinically warranted.
B. Baseline Individual Tolerability
-
If a patient takes immediate-release imeglimin with meals and experiences zero nausea, dyspepsia, or diarrhea,switching to SR yields negligible pharmacodynamic or therapeutic benefit. The daily receptor/mitochondrial exposure (AUC0−24AUC0−24) is functionally equivalent between 1,000 mg IR BID and an equivalent daily SR dose.
-
Conversely, if mild-to-moderate postprandial nausea or gastric discomfort occurs within 1 to 3 hours of taking IR,switching to SR is a medically sound first step before lowering the dose or abandoning therapy.
C. The Actual Pricing Spread
- In Domestic Generic Markets (e.g., India): The retail price differential between generic IR (such as standard generic 500 mg/1000 mg tablets) and generic SR (e.g., Imextor-SR ) is negligible—often within a margin of 5% to 20% (roughly ₹120 to ₹160 per strip of 10 tablets). At this price delta, the convenience and tolerability buffer of SR make it an obvious choice.
- In International/Import/Research Channels: Gray-market vendors or import services frequently attach a substantial 50% to 100%+ premium to extended-release formulations. If facing a heavy markup, paying extra is not cost-effective unless GI side effects are actively experienced on IR or the BID regimen cannot be maintained reliably.
1 Like